Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 versus salmeterol + fluticasone crossover study in adults with asthma
NL-OMON47676Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate and salmeterol + fluticasone in asthma (3 arms), sponsored by Novartis. Primary endpoint: Peak FEV1. Started May 2017; status: active, not recruiting.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoatesalmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON47676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47676.